A Sharply Defined Pattern of Central Retinal Thinning
A hole punch driven cleanly through a single page leaves a perfectly round gap while every other part of that page stays completely intact around it. Central areolar choroidal dystrophy leaves a comparable impression on a retinal examination — a sharply defined zone of atrophy sitting directly beneath the macula, with the surrounding retina and choroid remaining largely untouched. It's that crisp, clean edge, more than anything else, that tends to catch a specialist's attention first.
Zambian patients most often present with this condition in their thirties or forties, frequently after a routine eye check turned up a pale patch with an oddly precise border, something a local ophthalmologist correctly flagged as out of step with ordinary ageing at that stage of life.
The change tends to be subtle enough that people only piece it together in hindsight — small print that has quietly grown harder to read over a couple of years, or a habit of turning the head slightly so a face lands a little to the side of central vision rather than dead ahead. A sharply outlined dark or grey patch settles into the very centre of vision as things advance, yet everyday tasks like moving through a crowded room or finding a doorway stay entirely unaffected, since only that narrow central window is touched and low-light vision is left completely alone.
A fault in the PRPH2 gene explains most confirmed cases, a gene that ordinarily builds a structural protein photoreceptor cells rely on to hold their shape and carry out their function. Once that protein stops working, three closely connected layers beneath the macula — the choriocapillaris, the retinal pigment epithelium, and the photoreceptors sitting just above them — break down together, but the process stays boxed into that one narrow region rather than spreading outward. It's usually inherited as a dominant trait, appearing across successive generations.
What tends to stand out on examination is how unusually sharp the edge of the atrophic zone is, almost as though it had been traced with a ruler, and fundus autofluorescence is the tool relied on most to map that boundary with real precision. OCT shows how much photoreceptor tissue survives right at the margin — frequently the detail that matters most for planning ahead — while a near-normal ERG is genuinely reassuring, since it confirms the process has stayed contained rather than spreading. A PRPH2 genetic test rounds out the diagnostic picture.
Rather than following one fixed schedule, care is paced around how quickly the atrophic zone is actually expanding, tracked through repeat imaging over time rather than judged from a single visit. Patients who qualify are considered for regenerative stem cell therapy, aimed at supporting retina still functioning around the border of the affected zone, and as the central blind spot becomes more defined, we work through low-vision strategies suited to that individual's specific pattern of loss.
Not at all — if anything, it lines up with what we'd expect rather than casting any doubt on things. Because this condition stays confined to a small central zone and leaves the rod cells responsible for night vision untouched, seeing in the dark tends to remain reliable even as reading and recognising faces grow harder.
Not really a fixed one — some patients change very little across a decade of follow-up, while others progress more noticeably within just a few years. That's exactly why we rely on repeated imaging over time rather than predicting a single growth rate.
They can look strikingly alike side by side, but the cause and the timing are quite different — yours from an inherited gene fault showing up decades early, his from age-related change building up much later in life. A genetic test and the age of onset are what tell the two apart.
For most people, no — everyday orientation and mobility tend to stay reliable, since the disease keeps to a defined central area rather than reaching into the wider field of vision that guides how we move through the world.